|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
AU2007237096C1
(en)
|
2006-04-07 |
2012-12-13 |
EyePoint Pharmaceuticals, Inc. |
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
|
|
AU2009223838B2
(en)
|
2008-03-03 |
2012-07-26 |
The University Of Miami |
Allogeneic cancer cell-based immunotherapy
|
|
US8217149B2
(en)
|
2008-12-09 |
2012-07-10 |
Genentech, Inc. |
Anti-PD-L1 antibodies, compositions and articles of manufacture
|
|
SG178991A1
(en)
|
2009-09-03 |
2012-04-27 |
Schering Corp |
Anti-gitr antibodies
|
|
JP2013512251A
(ja)
*
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
PL2542590T5
(pl)
|
2010-03-05 |
2020-08-10 |
The Johns Hopkins University |
Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
|
|
DK2663579T3
(en)
|
2011-01-14 |
2017-07-31 |
Univ California |
THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
|
|
EP2686020B1
(en)
|
2011-03-17 |
2017-02-22 |
The University of Birmingham |
Re-directed immunotherapy
|
|
CA2831820C
(en)
*
|
2011-04-01 |
2021-05-25 |
Universitat Stuttgart |
Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
|
|
SG185920A1
(en)
|
2011-05-27 |
2012-12-28 |
Abbott Biotherapeutics Corp |
Dac hyp compositions and methods
|
|
US20130095065A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for Treating Vascular Leak Syndrome and Cancer
|
|
BR112014009526B8
(pt)
|
2011-10-17 |
2023-01-17 |
Herlev Hospital |
Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer
|
|
JP6602012B2
(ja)
*
|
2012-02-10 |
2019-11-06 |
シアトル ジェネティクス インコーポレーテッド |
Ｃｄ３０＋癌の検出と治療
|
|
PE20150605A1
(es)
|
2012-04-27 |
2015-05-28 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
|
|
NZ701821A
(en)
*
|
2012-04-30 |
2016-06-24 |
Biocon Ltd |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
CA2889298C
(en)
*
|
2012-11-30 |
2024-01-02 |
Anton Belousov |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
|
WO2014121085A1
(en)
*
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Pd-l1 and pd-l2-based fusion proteins and uses thereof
|
|
WO2014121099A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Agonist fusion protein for cd40 ox40 and uses thereof
|
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
|
WO2015116178A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
|
ES2885423T3
(es)
|
2013-02-07 |
2021-12-13 |
Massachusetts Gen Hospital |
Procedimientos para la expansión o el empobrecimiento de células T reguladoras
|
|
US9988456B2
(en)
|
2013-03-12 |
2018-06-05 |
Biocon Limited |
Fusion immunomodulatory proteins and methods for making same
|
|
NZ711567A
(en)
|
2013-03-13 |
2020-04-24 |
Genentech Inc |
Antibody formulations
|
|
WO2014168715A1
(en)
*
|
2013-04-08 |
2014-10-16 |
R-Pharm Overseas, Inc. |
B7 ligands/cd20 inhibitor composition and use thereof
|
|
CA2908198A1
(en)
|
2013-04-18 |
2014-10-23 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
BR112016001611B1
(pt)
|
2013-07-25 |
2024-01-09 |
Cytomx Therapeutics, Inc |
Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico
|
|
HK1225740A1
(zh)
|
2013-08-22 |
2017-09-15 |
Acceleron Pharma Inc. |
TGF-β受体II型变体及其用途
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
RU2016122957A
(ru)
*
|
2013-11-11 |
2017-12-19 |
Армо Байосайенсиз, Инк. |
Способы применения интерлейкина-10 для лечения заболеваний и расстройств
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
US11213583B2
(en)
*
|
2014-02-05 |
2022-01-04 |
Cedars-Sinai Medical Center |
Methods and compositions for treating cancer and infectious diseases
|
|
SG10202108879SA
(en)
*
|
2014-02-10 |
2021-09-29 |
Merck Patent Gmbh |
TARGETED TGFβ INHIBITION
|
|
US20170165364A1
(en)
*
|
2014-02-21 |
2017-06-15 |
Idac Theranostics, Inc. |
Therapeutic agent for solid cancer
|
|
US10532088B2
(en)
|
2014-02-27 |
2020-01-14 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
|
|
CA2936962C
(en)
|
2014-03-14 |
2024-03-05 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
US20150307620A1
(en)
*
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
|
US9896441B2
(en)
|
2014-05-05 |
2018-02-20 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
EP3209641A4
(en)
|
2014-05-05 |
2018-06-06 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
|
|
CN103965364B
(zh)
*
|
2014-05-19 |
2016-06-08 |
亚飞（上海）生物医药科技有限公司 |
一种人源pdl2hsa系列融合蛋白及其制备与应用
|
|
WO2015178746A1
(ko)
*
|
2014-05-23 |
2015-11-26 |
주식회사 제넥신 |
Pd-l1 융합 단백질 및 이의 용도
|
|
SG10201912986PA
(en)
|
2014-05-28 |
2020-02-27 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
|
CA2951234C
(en)
|
2014-06-06 |
2022-05-31 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
US11168137B2
(en)
|
2014-06-11 |
2021-11-09 |
Idac Theranostics, Inc. |
Method for reducing side effects of immune checkpoint control agent
|
|
KR102493543B1
(ko)
*
|
2014-07-21 |
2023-01-30 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
PL3482766T3
(pl)
|
2014-08-11 |
2020-11-16 |
Delinia, Inc. |
Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
EP3193932B1
(en)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
TWI757803B
(zh)
|
2014-11-14 |
2022-03-11 |
瑞士商赫孚孟拉羅股份公司 |
包含tnf家族配位三聚體之抗原結合分子
|
|
WO2016118577A1
(en)
*
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
IL284985B2
(en)
|
2015-02-18 |
2023-03-01 |
Enlivex Therapeutics R& D Ltd |
Combined immunotherapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
BR112017018224A2
(pt)
*
|
2015-03-11 |
2018-04-17 |
Cellectis |
métodos para manipulação de célula t alogênica para aumentar sua persistência e/ou implante em pacientes
|
|
JP6826055B2
(ja)
|
2015-03-13 |
2021-02-03 |
サイトメックス セラピューティクス インコーポレイテッド |
抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
|
|
EP3277305B1
(en)
|
2015-03-31 |
2021-07-21 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a trimeric tnf family ligand
|
|
EP3281010B1
(en)
|
2015-04-10 |
2020-12-30 |
The Regents of The University of California |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
|
PT3283508T
(pt)
|
2015-04-17 |
2021-06-21 |
Alpine Immune Sciences Inc |
Proteínas imuno modulatórias com afinidades afináveis
|
|
CA2982452A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
AU2016258977C1
(en)
*
|
2015-05-04 |
2022-07-14 |
Pieris Pharmaceuticals Gmbh |
Anti-cancer fusion polypeptide
|
|
JP2018515491A
(ja)
|
2015-05-05 |
2018-06-14 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
|
|
CN115109158A
(zh)
|
2015-05-07 |
2022-09-27 |
阿吉纳斯公司 |
抗ox40抗体及其使用方法
|
|
CN107849142B
(zh)
|
2015-05-15 |
2022-04-26 |
综合医院公司 |
拮抗性抗肿瘤坏死因子受体超家族抗体
|
|
US10690674B2
(en)
|
2015-06-03 |
2020-06-23 |
Bristol-Myers Squibb Company |
Anti-GITR antibodies for cancer diagnostics
|
|
JP6838004B2
(ja)
|
2015-06-11 |
2021-03-03 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
|
|
US10513558B2
(en)
|
2015-07-13 |
2019-12-24 |
Cytomx Therapeutics, Inc. |
Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
|
|
CN111375066B
(zh)
|
2015-07-16 |
2023-04-25 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
MA42459A
(fr)
|
2015-07-16 |
2018-05-23 |
Bioxcel Therapeutics Inc |
Nouvelle approche pour le traitement du cancer par immunomodulation
|
|
WO2017019729A1
(en)
|
2015-07-27 |
2017-02-02 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
|
EP3331550B1
(en)
|
2015-08-04 |
2022-11-02 |
Acceleron Pharma Inc. |
Composition for treating myeloproliferative disorders
|
|
KR20180038553A
(ko)
|
2015-08-25 |
2018-04-16 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
|
US20190135929A1
(en)
|
2015-08-28 |
2019-05-09 |
The General Hospital Corporation |
Agonistic anti-tumor necrosis factor receptor 2 antibodies
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
WO2017037634A1
(en)
*
|
2015-08-31 |
2017-03-09 |
National Research Council Of Canada |
Tgf-β-receptor ectodomain fusion molecules and uses thereof
|
|
US20180251548A1
(en)
*
|
2015-09-14 |
2018-09-06 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta
|
|
RU2766200C1
(ru)
|
2015-10-01 |
2022-02-09 |
Хит Байолоджикс, Инк. |
Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
RS62258B1
(sr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Bispecifična antitela specifična za pd1 i tim3
|
|
KR20180053674A
(ko)
|
2015-10-02 |
2018-05-23 |
에프. 호프만-라 로슈 아게 |
공자극 tnf 수용체에 특이적인 이중특이성 항체
|
|
US20170107510A1
(en)
*
|
2015-10-14 |
2017-04-20 |
Batu Biologics, Inc. |
Dna nanoparticle based checkpoint inhibitors
|
|
MX2018005315A
(es)
*
|
2015-10-30 |
2018-08-14 |
Aleta Biotherapeutics Inc |
Composiciones y metodos para el tratamiento del cancer.
|
|
AU2016343805A1
(en)
|
2015-10-30 |
2018-06-07 |
Aleta Biotherapeutics Inc. |
Compositions and methods for tumor transduction
|
|
US11219645B2
(en)
|
2015-11-18 |
2022-01-11 |
Duke University |
Tumor infiltrating lymphocytes for treatment of cancer
|
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
IL299072A
(en)
|
2015-12-02 |
2023-02-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies and methods of use thereof
|
|
BR112018012352A2
(pt)
|
2015-12-16 |
2018-12-11 |
Merck Sharp & Dohme Corp. |
anticorpos anti-lag3 e fragmentos de ligação ao antígeno
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2017129537A1
(en)
*
|
2016-01-25 |
2017-08-03 |
Sanofi |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
|
|
WO2017134592A1
(en)
*
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
US11730761B2
(en)
|
2016-02-18 |
2023-08-22 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
EP3455262A4
(en)
*
|
2016-05-13 |
2020-04-08 |
The General Hospital Corporation |
ANTAGONIST ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY AGAINST TUMORS
|
|
WO2017200796A1
(en)
|
2016-05-17 |
2017-11-23 |
Albert Einstein College Of Medicine, Inc. |
Engineered pd-1 variants
|
|
AU2017268469C1
(en)
*
|
2016-05-20 |
2025-01-02 |
President And Fellows Of Harvard College |
Gene therapy methods for age-related diseases and conditions
|
|
KR20230091191A
(ko)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
US20200339659A1
(en)
|
2016-06-21 |
2020-10-29 |
Io Biotech Aps |
Pdl1 peptides for use in cancer vaccines
|
|
CA3029902A1
(en)
|
2016-07-07 |
2018-01-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antibody adjuvant conjugates
|
|
CN118307682A
(zh)
*
|
2016-09-27 |
2024-07-09 |
埃皮辛特瑞柯斯公司 |
免疫调节性融合蛋白
|
|
BR112019007369A2
(pt)
|
2016-10-11 |
2019-07-16 |
Agenus Inc |
anticorpos anti-lag-3 e métodos de uso dos mesmos
|
|
WO2018071837A1
(en)
*
|
2016-10-14 |
2018-04-19 |
Baylor College Of Medicine |
Radiofrequency field hyperthermia and solid tumor immunomodulation
|
|
US20190256573A1
(en)
*
|
2016-10-14 |
2019-08-22 |
Emory University |
Nanoparticles Having Molecules That Bind or Block PD-L1 and Uses In Treating Cancer
|
|
EA201991142A1
(ru)
|
2016-11-08 |
2019-10-31 |
|
Варианты il-2 для лечения аутоиммунных заболеваний
|
|
WO2018089628A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
CA3082255A1
(en)
|
2016-11-23 |
2020-06-10 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
|
US11230596B2
(en)
|
2016-11-30 |
2022-01-25 |
Mereo Biopharma 5, Inc. |
Methods for treatment of cancer comprising TIGIT-binding agents
|
|
MA46963A
(fr)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics Inc |
Méthodes pour déterminer le dosage de céllules car-t
|
|
US20190350978A1
(en)
|
2016-12-05 |
2019-11-21 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
|
AU2018205888B2
(en)
|
2017-01-05 |
2021-09-02 |
Kahr Medical Ltd. |
A PD1-41BBL fusion protein and methods of use thereof
|
|
US11566060B2
(en)
|
2017-01-05 |
2023-01-31 |
Kahr Medical Ltd. |
PD1-CD70 fusion protein and methods of use thereof
|
|
US11299530B2
(en)
|
2017-01-05 |
2022-04-12 |
Kahr Medical Ltd. |
SIRP alpha-CD70 fusion protein and methods of use thereof
|
|
SI3565828T1
(sl)
|
2017-01-05 |
2022-04-29 |
Kahr Medical Ltd. |
SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
|
|
AU2018205233A1
(en)
*
|
2017-01-07 |
2019-07-11 |
Merck Patent Gmbh |
Dosing regimens and dosage forms for targeted TGFβ inhibition
|
|
TWI787230B
(zh)
|
2017-01-20 |
2022-12-21 |
法商賽諾菲公司 |
抗ＴＧＦ-β抗體及其用途
|
|
TW202421659A
(zh)
|
2017-01-20 |
2024-06-01 |
美商健臻公司 |
骨靶向抗體
|
|
CA3051696A1
(en)
*
|
2017-02-01 |
2018-08-09 |
Acceleron Pharma Inc. |
Tgf.beta. and actrii antagonists for use in increasing immune activity
|
|
IL268346B2
(en)
|
2017-02-06 |
2024-08-01 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
|
KR102745835B1
(ko)
|
2017-02-27 |
2024-12-24 |
샤턱 랩스 인코포레이티드 |
Tigit- 및 light-기반 키메라 단백질
|
|
CN118184797A
(zh)
|
2017-02-27 |
2024-06-14 |
沙塔克实验室有限公司 |
基于vsig8的嵌合蛋白
|
|
CA3054132A1
(en)
|
2017-02-27 |
2018-08-30 |
Shattuck Labs, Inc. |
Csf1r-based chimeric proteins
|
|
CN118255902A
(zh)
|
2017-03-02 |
2024-06-28 |
加拿大国家研究委员会 |
TGF-β受体胞外域融合分子及其用途
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
EP3596469A1
(en)
|
2017-03-12 |
2020-01-22 |
Yeda Research and Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
BR112019019973A2
(pt)
*
|
2017-03-24 |
2020-04-28 |
Orpheus Bioscience Inc |
pantlds para tratamento de transtornos autoimunes
|
|
CN107082812B
(zh)
*
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
JP7426825B2
(ja)
|
2017-04-03 |
2024-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
|
|
US11285207B2
(en)
|
2017-04-05 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specifically binding to PD1 and LAG3
|
|
JP2020517256A
(ja)
|
2017-04-19 |
2020-06-18 |
エルスター セラピューティクス， インコーポレイテッド |
多重特異性分子およびその使用
|
|
US11643473B2
(en)
|
2017-04-24 |
2023-05-09 |
Alexion Pharmaceuticals, Inc. |
Antibody immune cell inhibitor fusion proteins
|
|
EP3618863B1
(en)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
EP4241848A3
(en)
|
2017-05-04 |
2023-11-01 |
Acceleron Pharma Inc. |
Tgf-beta receptor type ii fusion proteins and uses thereof
|
|
WO2018205985A1
(zh)
|
2017-05-12 |
2018-11-15 |
江苏恒瑞医药股份有限公司 |
含有TGF-β受体的融合蛋白及其医药用途
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
JP7356354B2
(ja)
|
2017-05-12 |
2023-10-04 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
|
|
CN110869392A
(zh)
|
2017-05-16 |
2020-03-06 |
百时美施贵宝公司 |
用抗gitr激动性抗体治疗癌症
|
|
WO2018213747A1
(en)
*
|
2017-05-19 |
2018-11-22 |
Merrimack Pharmaceuticals, Inc. |
4-1bb agonist and cd40 agonist bispecific molecules
|
|
EA201992755A1
(ru)
|
2017-05-19 |
2020-04-22 |
Уси Байолоджикс (Шанхай) Ко. Лтд. |
Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
|
|
CN111432828A
(zh)
*
|
2017-05-26 |
2020-07-17 |
约翰霍普金斯大学 |
用以调节免疫耐受的多功能抗体-配体捕获剂
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
|
CN107857819A
(zh)
*
|
2017-07-03 |
2018-03-30 |
江苏西迪尔生物技术有限公司 |
多功能融合蛋白及其应用
|
|
PL3661954T3
(pl)
|
2017-08-03 |
2022-05-16 |
Amgen Inc. |
Muteiny interleukiny 21 i sposoby leczenia
|
|
AU2018309339C1
(en)
|
2017-08-04 |
2025-08-21 |
BioNTech SE |
Binding agents binding to PD-L1 and CD137 and use thereof
|
|
CN107602705B
(zh)
*
|
2017-09-13 |
2018-08-31 |
北京鼎成肽源生物技术有限公司 |
一种基于蛋白互作用于检测细胞pd1表达情况的融合蛋白及其应用
|
|
CA3077223A1
(en)
|
2017-09-27 |
2019-04-04 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
|
EP3688022A4
(en)
*
|
2017-09-29 |
2021-09-22 |
NantCell, Inc. |
ANTIGEN PROTEINS AND PROCEDURES FOR THEREFORE
|
|
CA3077509A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
CA3079264A1
(en)
*
|
2017-10-18 |
2019-04-25 |
Intrexon Corporation |
Polypeptide compositions comprising spacers
|
|
JP2021502360A
(ja)
*
|
2017-11-09 |
2021-01-28 |
メディミューン，エルエルシー |
二重特異的融合ポリペプチド及びその使用方法
|
|
EP3716980A1
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
|
WO2019113123A1
(en)
*
|
2017-12-04 |
2019-06-13 |
Precithera, Inc. |
TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
|
|
JP7348899B2
(ja)
*
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性分子及びその使用
|
|
AU2019205273B2
(en)
|
2018-01-03 |
2024-04-04 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
CN111727197A
(zh)
|
2018-01-12 |
2020-09-29 |
美国安进公司 |
抗pd-1抗体和治疗方法
|
|
CN110151309B
(zh)
*
|
2018-02-14 |
2022-02-15 |
上海美杰医疗科技有限公司 |
多模态消融治疗术前规划方法及其设备
|
|
US10780120B2
(en)
*
|
2018-03-06 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
JP7319992B2
(ja)
|
2018-03-09 |
2023-08-02 |
アジェナス インコーポレイテッド |
抗ｃｄ７３抗体およびそれらの使用方法
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3773657A4
(en)
*
|
2018-03-26 |
2021-12-08 |
Altor Bioscience LLC |
ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES
|
|
AU2019256383A1
(en)
|
2018-04-17 |
2020-11-26 |
Celldex Therapeutics, Inc. |
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
|
|
US12103959B2
(en)
|
2018-05-03 |
2024-10-01 |
Acceleron Pharma Inc. |
Multispecific binders of TGFBeta-superfamily ligands and uses thereof
|
|
US12168683B2
(en)
|
2018-05-03 |
2024-12-17 |
Acceleron Pharma Inc. |
Binders of TGFβ-superfamily ligands and uses thereof
|
|
KR20210006405A
(ko)
*
|
2018-05-04 |
2021-01-18 |
메르크 파텐트 게엠베하 |
암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
|
|
SG11202011080QA
(en)
|
2018-05-11 |
2020-12-30 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
CA3103427A1
(en)
*
|
2018-06-15 |
2019-12-19 |
Acceleron Pharma Inc. |
Bi-and tri-functional fusion proteins and uses thereof
|
|
WO2019246563A1
(en)
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
US11001635B2
(en)
*
|
2018-06-29 |
2021-05-11 |
Gensun Biopharma Inc. |
Antitumor antagonists
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
KR20210042909A
(ko)
*
|
2018-07-09 |
2021-04-20 |
프레시전 인코포레이티드 |
융합 구조물 및 그의 이용 방법
|
|
CA3104780A1
(en)
|
2018-07-11 |
2020-01-16 |
Kahr Medical Ltd. |
Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
|
|
US12286466B2
(en)
|
2018-07-11 |
2025-04-29 |
Kahr Medical Ltd. |
PD1-4-1BBL variant fusion protein and methods of use thereof
|
|
EP3833391A4
(en)
|
2018-08-08 |
2022-08-10 |
Orionis Biosciences, Inc. |
CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES
|
|
US10780121B2
(en)
|
2018-08-29 |
2020-09-22 |
Shattuck Labs, Inc. |
FLT3L-based chimeric proteins
|
|
WO2020047329A1
(en)
*
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
|
CN109053895B
(zh)
|
2018-08-30 |
2020-06-09 |
中山康方生物医药有限公司 |
抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
|
|
JP7695187B2
(ja)
|
2018-09-24 |
2025-06-18 |
アイポイント ファーマシューティカルズ， インコーポレイテッド |
ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
|
|
WO2020069372A1
(en)
|
2018-09-27 |
2020-04-02 |
Elstar Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
|
US20220034880A1
(en)
*
|
2018-10-01 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
High specificity and sensitivity immunosorbent diagnostic assays with simultaneous resolution of multiple antibody isotypes
|
|
BR112021007318A2
(pt)
|
2018-10-17 |
2021-08-31 |
Biolinerx Ltd. |
Tratamento de adenocarcinoma pancreático metastático
|
|
CA3114803A1
(en)
*
|
2018-10-24 |
2020-04-30 |
Shire-Nps Pharmaceuticals, Inc. |
Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
|
|
EP3873611A1
(en)
|
2018-11-01 |
2021-09-08 |
Merck Patent GmbH |
Anti-tim-3 antibodies
|
|
CA3117371A1
(en)
|
2018-11-01 |
2020-05-07 |
Merck Patent Gmbh |
Methods of administering anti-tim-3 antibodies
|
|
KR102881644B1
(ko)
|
2018-11-09 |
2025-11-06 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
TGF-β 수용체 융합 단백질 약학적 조성물 및 이의 용도
|
|
US20220025061A1
(en)
*
|
2018-12-10 |
2022-01-27 |
Bioxcel Therapeutics, Inc. |
Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
|
|
KR20210142594A
(ko)
|
2018-12-26 |
2021-11-25 |
시티 오브 호프 |
활성화 가능한 차폐된 항-ctla4 결합 단백질
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
CA3130628A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
CA3130794A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
CA3134144A1
(en)
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
JP2022531185A
(ja)
|
2019-04-30 |
2022-07-06 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
遺伝子改変ｔ細胞を標的化するｃｄ１９を使用するｂ細胞悪性病変の同種細胞療法
|
|
US12109235B2
(en)
*
|
2019-06-21 |
2024-10-08 |
Kite Pharma, Inc. |
TGF-beta receptors and methods of use
|
|
EP3986920B1
(en)
|
2019-06-24 |
2025-04-16 |
Universität Stuttgart |
Tnfr2 agonists with improved stability
|
|
EP3990116A1
(en)
|
2019-06-28 |
2022-05-04 |
Gensun Biopharma Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
WO2021011864A1
(en)
*
|
2019-07-18 |
2021-01-21 |
Memorial Sloan Kettering Cancer Center |
METHODS AND COMPOSITIONS FOR TARGETING TGF-β SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
|
|
WO2021025140A1
(ja)
*
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
CN114787196A
(zh)
*
|
2019-08-29 |
2022-07-22 |
南特生物科学公司 |
修饰的n-810及其方法
|
|
US20220289825A1
(en)
*
|
2019-08-30 |
2022-09-15 |
Nanjing Shunxin Pharmaceuticals Co., Ltd., Of Chiatai Tianqing Pharmaceutical Group |
FUSION PROTEIN TARGETING PD-L1 AND TGF-ß AND USE THEREOF
|
|
CN115151635A
(zh)
*
|
2019-09-18 |
2022-10-04 |
斯比根公司 |
用编码新的嵌合抗原受体的基因转导的基因修饰nk细胞系及其用途
|
|
CN110734498A
(zh)
*
|
2019-10-15 |
2020-01-31 |
上海科棋药业科技有限公司 |
一种用于解除免疫抑制的融合蛋白及其应用
|
|
EP4048704A4
(en)
|
2019-10-21 |
2023-11-22 |
Nanjing Leads Biolabs Co., Ltd. |
RECOMBINANT PROTEIN TARGETING PD-1 AND TGFß
|
|
WO2021081258A1
(en)
|
2019-10-23 |
2021-04-29 |
Cue Biopharma, Inc. |
TGF-β POLYPEPTIDES
|
|
WO2021093760A1
(zh)
*
|
2019-11-12 |
2021-05-20 |
江苏恒瑞医药股份有限公司 |
含有TGF-β受体的融合蛋白及其医药用途
|
|
WO2021104434A1
(en)
*
|
2019-11-27 |
2021-06-03 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
TGFβ/PD-L1 BISPECIFIC BINDING PROTEINS
|
|
AU2020391231A1
(en)
|
2019-11-27 |
2022-07-14 |
Turnstone Biologics Corp. |
Method of producing tumor-reactive T cell composition using modulatory agents
|
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
|
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
CN115103685B
(zh)
*
|
2020-01-23 |
2025-08-05 |
格纳西尼有限公司 |
包含程序性细胞死亡配体1蛋白的融合蛋白及其用途
|
|
US11912751B2
(en)
*
|
2020-01-31 |
2024-02-27 |
Globetek Science Foundation |
Bi-functional fusion proteins comprised of TGF-B and immune checkpoint domains
|
|
IL295934A
(en)
|
2020-02-27 |
2022-10-01 |
Myst Therapeutics Llc |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
WO2021209049A1
(zh)
*
|
2020-04-16 |
2021-10-21 |
南通壹宸生物医药科技有限公司 |
一种pd-1突变体多肽及其制备和用途
|
|
JP2023523011A
(ja)
|
2020-04-24 |
2023-06-01 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
AU2021264846B2
(en)
*
|
2020-04-28 |
2025-03-06 |
Sinocelltech Ltd. |
TGFβR2 extracellular domain truncated molecule, fusion protein of TGFβR2 extracellular domain truncated molecule and anti-EGFR antibody, and anti-tumor use of fusion protein
|
|
CN111690070A
(zh)
*
|
2020-05-13 |
2020-09-22 |
深圳市众循精准医学研究院 |
一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
|
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
AU2021305234A1
(en)
*
|
2020-07-10 |
2023-02-09 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
MX2023004725A
(es)
*
|
2020-10-23 |
2024-02-23 |
Hq Han |
Antagonistas bifuncionales del factor de necrosis tumoral alfa y del factor de crecimiento transformante beta y usos de los mismos.
|
|
MX2023005565A
(es)
*
|
2020-11-11 |
2024-02-23 |
Hq Han |
Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos.
|
|
CN114539415B
(zh)
*
|
2020-11-24 |
2024-02-02 |
普米斯生物技术(珠海)有限公司 |
一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
|
|
US20240082394A1
(en)
*
|
2020-12-15 |
2024-03-14 |
Bicara Therapeutics Inc. |
Combination therapy for the treatment of cancer
|
|
JP2023553209A
(ja)
*
|
2020-12-15 |
2023-12-20 |
バイカラ セラピューティクス インコーポレイテッド |
融合タンパク質の医薬製剤
|
|
EP4294422A4
(en)
*
|
2021-02-17 |
2025-04-02 |
Cura Therapeutics, Inc. |
ANTI-PATHOGEN INTERLEUKIN-TGF-BETA RECEPTOR FUSION POLYPEPTIDES
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
AU2022291370A1
(en)
*
|
2021-06-07 |
2024-01-04 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for targeted delivery of therapeutic agents
|
|
WO2023004377A1
(en)
*
|
2021-07-21 |
2023-01-26 |
Mayo Foundation For Medical Education And Research |
Promoting immune surveillance against cancer cells
|
|
WO2023027561A1
(ko)
*
|
2021-08-27 |
2023-03-02 |
세라노틱스(주) |
B7-h3 및 tgfβ에 특이적으로 결합하는 이중 특이적 분자 및 이의 용도
|
|
AU2022350320A1
(en)
*
|
2021-09-24 |
2024-04-11 |
Bionsystems Inc |
Fusion protein dimer including pd-1 and il-21, and use thereof
|
|
JP2024536932A
(ja)
|
2021-10-11 |
2024-10-08 |
ワイ－トラップ， インコーポレイテッド |
Ｉｌ－２３シグナル伝達を阻害する組成物および方法
|
|
JP2024544534A
(ja)
*
|
2021-11-11 |
2024-12-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ２０－ｐｄ１結合分子及びその使用方法
|
|
EP4514834A1
(en)
*
|
2022-04-28 |
2025-03-05 |
Immatics US, Inc. |
Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
|
|
CA3260155A1
(en)
*
|
2022-06-29 |
2024-01-04 |
Cdres Pharma Llc |
Immunologically active polypeptide
|
|
WO2024215772A2
(en)
*
|
2023-04-11 |
2024-10-17 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
AU2024204722A1
(en)
*
|
2023-05-31 |
2024-12-19 |
Fbd Biologics Limited |
Cd47/pd-l1-targeting protein complex and methods of use thereof
|
|
CN116514913B
(zh)
*
|
2023-06-07 |
2025-03-21 |
澳门大学 |
具有抗肿瘤活性的tnfr2靶向肽及其应用
|
|
TW202517668A
(zh)
*
|
2023-06-26 |
2025-05-01 |
寶泰生醫股份有限公司 |
治療癌症的組合物與方法
|